Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
This is a single-arm, open-label phase II study with a safety lead-in phase.
Trial Details
- NCT ID
- NCT04240054
- Phase
- PHASE2
- Sponsor
- Medical College of Wisconsin
- Status
- RECRUITING
- Cancer Type
- Multiple Myeloma
- Interventions
- Bortezomib
- Isatuximab
- Cyclophosphamide
- Dexamethasone
- Locations (sample)
- Milwaukee, Wisconsin, United States|43.0389,-87.90647
Key Eligibility Criteria
- Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding…
- Male or female subjects ≥18 years.
- Patients must be eligible for high-dose therapy and autologous stem cell transplantation as per institutional guidelines.
- No prior multiple myeloma (MM) -directed therapy except for dexamethasone (up to 160 mg), bortezomib (up to 5.2 mg/m\^2) and/or cyclophosphamide up…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →